Pox­el pass­es 3rd straight Phase III di­a­betes tri­al in Japan, but what's go­ing on with US/EU part­ner Roivant?

Pox­el and its new di­a­betes tablet are head­ing to reg­u­la­tors. Well, in Japan at least.

The French phar­ma and its Japan­ese part­ner Sum­it­o­mo Dainip­pon an­nounced the third straight Phase III suc­cess for its new kind of di­a­betes tablet. In the year-long, open-la­bel TIMES 2 tri­al, Imeglim­in de­creased blood sug­ar lev­els (HbA1c) as a monother­a­py or in com­bi­na­tion with one of any of 8 com­mon di­a­betes drugs. That in­clud­ed a .92% de­cline when giv­en with DDP-4 in­hibitors, one of the most com­mon di­a­betes meds in Japan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER